Alkermes plc. Proceeds from Common Stock Issued
Alkermes plc. (ALKS) reported Proceeds from Common Stock Issued of $248.41 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2017-02-17
- Alkermes plc. proceeds from issuance of common stock for the quarter ending 2014-12-31 was $0.00.
- Alkermes plc. proceeds from issuance of common stock for the quarter ending 2014-09-30 was $0.00.
- Alkermes plc. proceeds from issuance of common stock for the quarter ending 2014-06-30 was $0.00.
- Alkermes plc. proceeds from issuance of common stock for the quarter ending 2014-03-31 was $248.41M.
- Alkermes plc. proceeds from issuance of common stock for fiscal 2014 was $248.41M.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | $0.00 derived: sum of 3 quarters · filed 2017-02-17 | $248.41M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $0.00 derived: sum of 2 quarters · filed 2015-10-29 | $248.41M 10-Q · filed 2015-10-29 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $248.41M 10-Q · filed 2015-07-30 | |||
| 2014-03-31 | $248.41M 10-Q · filed 2015-04-30 | ||||
| 2014-01-31 | $250.00M 10-Q · filed 2014-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |